AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (original) A pharmaceutical composition which comprises an active pharmaceutical ingredient and a non-detergent sulfobetaine (NDSB).

2. (original) The pharmaceutical composition according to claim 1, wherein the active pharmaceutical ingredient is selected from the group consisting of a therapeutically effective synthetic or natural organic molecule and a therapeutically effective protein.

3. (original) The pharmaceutical composition according to claim 2, wherein the therapeutically effective protein is selected from the group consisting of granulocyte-colony stimulating factor, interferons, interleukins, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, epidermal growth factor, erythropoietin, follicle-stimulating hormone, human serum albumin, deoxyribonuclease, fibroblast calcitonin, hematoprotein; plasminogenic activators and their precursors, cytokines; TNF family of ligands, soluble receptors, growth hormones, lipoproteins; alpha-1-antitrypsin; insulin, proinsulin, subunit A of insulin, subunit B of insulin; glucagons; blood coagulation factors, bombasine; thrombin; enkephalinase; macrophage inflammatory protein (MIP-1-alpha); relaxin A subunit, relaxin B subunit, prorelaxin; inhibin; activin; vascular endothelial growth factor; hormone receptors or growth factor receptors; integrins; protein A, protein D; rheumatoid factors; bone-derived neurotrophic factor, neurotropin-3, -4, -5, or 6; nerve growth factor, platelet-derived growth factor, fibroblast growth factor, transformed growth factor, insulin-like growth factor, thrombopoietin, bone morphogenetic protein and superoxide dismutase.

4. (original) The pharmaceutical composition according to claim 3, wherein the therapeutically effective protein is G-CSF.

5. (previously presented) The pharmaceutical composition according to claim 1, wherein the NDSB is quaternary ammonium salt of Formula 1, wherein R1, R2 and R3 can be the same

and/or different and are selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl or their derivatives, and R4 is $(CH_2)_n$, wherein n is between 1 and 6.

6. (original) The pharmaceutical composition according to claim 5, wherein the NDSB is selected from the group consisting of dimethylethyl-(3-sulphopropyl)-ammonium salt, 3-(1-pyridino)-1-propanesulfonate, dimethylbenzylammonium propanesulfonate, dimethyl-t-butyl-(3-sulphopropyl)ammonium salt, 3-(1-methylpiperidine)-1-propanesulfonate and dimethyl-(2-hydroxyethyl)-(sulphopropyl)-ammonium salt.

7. (original) The pharmaceutical composition according to claim 6, wherein the NDSB is dimethyl-t-butyl-(3-sulphopropyl)ammonium salt.

8. (previously presented) The pharmaceutical composition according to claim 1 wherein said composition optionally further comprises a polyol.

9. (original) The pharmaceutical composition according to claim 8, wherein the polyol is selected from the group consisting of sorbitol, glycerol, inositol, trehalose and mannitol.

10. (previously presented) The pharmaceutical composition according claim 1, wherein said composition optionally further comprises one or more pharmaceutically acceptable excipients.

11. (original) The pharmaceutical composition according to claim 10, wherein a pharmaceutically acceptable excipient is selected from the group consisting of EDTA and DMSO.

12. (currently amended) A process for preparation of a pharmaceutical composition, wherein [[a]]<u>the</u> pharmaceutical composition of claim 1 is prepared by mixing a NDSB with therapeutically effective amount of an active pharmaceutical ingredient.

13. (cancelled)

14. (withdrawn) A method of using a NDSB as a stabiliser in a pharmaceutical composition.

15. (withdrawn) A method of using a NDSB as a buffering agent in a pharmaceutical composition.

16. (withdrawn) A method of using a NDSB as a pH adjusting agent in a pharmaceutical composition.